ArticleFuture healthcare journal2025
Rethinking pharmaceutical development: A not-for-profit model to address global health inequities.
Article in Future healthcare journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Priority without progress: the FDA's neglected tropical disease voucher program after 18 years.Health affairs scholar · 2026Article
- Global health is in crisis: to reach neglected patients, we need to reimagine medical research.BMJ global health · 2026Article
- Intelligent information management enables quality-by-design in pharmaceutical production.Scientific reports · 2025Article
- If commercial incentives are the engine, then conflicts of interest are the lubricant.Future healthcare journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern pharmaceuticals represent some of the greatest achievements in science and economic development. Yet, despite significant progress, profound inequities in access to essential medicines persist, particularly in low- and middle-income countries (LMICs). Traditional market-driven pharmaceutical models have succeeded where strong commercial incentives exist, but have failed to deliver for diseases with limited market potential, particularly in the neglected tropical diseases. This article outlines the reasons for inequity within the current system, the role of not-for-profit pharmaceutical development, and the urgent need for a new, complementary model for access that centres on public health priorities rather than market return.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.